The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- 1 December 2009
- journal article
- research article
- Published by Elsevier in Cancer Cell
- Vol. 16 (6) , 487-497
- https://doi.org/10.1016/j.ccr.2009.10.015
Abstract
No abstract availableKeywords
Funding Information
- AstraZeneca
- National Institutes of Health (CA115674)
This publication has 54 references indexed in Scilit:
- Sunitinib Inhibition of Stat3 Induces Renal Cell Carcinoma Tumor Cell Apoptosis and Reduces Immunosuppressive CellsCancer Research, 2009
- IL-6 and Stat3 Are Required for Survival of Intestinal Epithelial Cells and Development of Colitis-Associated CancerCancer Cell, 2009
- Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomasJournal of Clinical Investigation, 2007
- Epidermal Growth Factor Receptor Cooperates with Signal Transducer and Activator of Transcription 3 to Induce Epithelial-Mesenchymal Transition in Cancer Cells via Up-regulation of TWIST Gene ExpressionCancer Research, 2007
- Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinaseProceedings of the National Academy of Sciences, 2007
- Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironmentNature Reviews Immunology, 2007
- STAT3: A multifaceted oncogeneProceedings of the National Academy of Sciences, 2006
- The STATs of cancer — new molecular targets come of ageNature Reviews Cancer, 2004
- Constitutive Stat3 activity up-regulates VEGF expression and tumor angiogenesisOncogene, 2002
- STATs in oncogenesisOncogene, 2000